Service uses simulation modeling methodology to evaluate the quantity of medication produced for use in clinical development.
E-Clinical and Regulatory solutions and services provider Calyx has announced its Calyx Supply Simulation clinical trial supply forecasting service. Available through the company’s in-house statistical design and trial supplies consultants, the service uses simulation modeling methodology and over 50 design parameters that closely mimic an Interactive Response Technology (IRT) system, to evaluate the quantity of medication produced for use in clinical development.
By providing better-aligned medication scenarios—for trial start-up and continued enrollment, how long an existing amount of study medication will last and determining optimal site and depot buffer stock quantities—can help sponsors reduce cost and excessive drug wastage.
Reference: Calyx Launches Supply Simulation Service to Forecast and Optimize Clinical Trial Supplies; Nottingham, England and Morrisville, NC. March 7, 2023
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.